Radar · Biopharma Outsourcing in California
Best Biopharma Outsourcing Companies in California, United States
The 375 best Biopharma Outsourcing companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Resilience.
By Riya SenguptaFinancials
375companies tracked
$5.3Bdisclosed funding
0unicorns
116have raised
FLIAR INTELLIGENCE · BIOPHARMA OUTSOURCING × CALIFORNIA
Our analysis of 50 Biopharma Outsourcing companies
$6.3b in tracked funding; 77% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
77%cloud-native stacks
2025funding peak (by rounds)
2018median founding year
45median Fliar Index™
240kcombined LinkedIn audience
44%of audience held by top 3
5companies hiring publicly (12 mo)
Ranked: Best Biopharma Outsourcing companies in California
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Resilience Provider of supply chain services for biopharma sector 72Funding top 15%Product top 26%Innovation top 30%Growth top 35% All 9 signals ▾Fundingtop 15% Producttop 26% Innovationtop 30% Growthtop 35% Markettop 43% Techtop 43% Talentbottom 49% Globalbottom 38% Moatbottom 38% Funding: Raised $2.0B across 10 rounds · 10 rounds over 20 yrs (0.5/yr) Product: 3 distinct product lines · Company stage: Series D rank vs industry peers · Fliar Intelligence Index 72/100 | $2.0B | 7 mo ago | 1,767 | Rahul Singhvi ex-Co-Founder | — | 1 expansion |
| 2 | Kardigan Biotech company developing personalized medicines for cardiovascular diseases 60Funding top 14%Growth top 28%Tech top 48%Talent bottom 49% All 6 signals ▾Fundingtop 14% Growthtop 28% Techtop 48% Talentbottom 49% Marketbottom 35% Globalbottom 33% Funding: Raised $554M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $554M | 8 mo ago | — | Tassos Gianakakos Co-Founder & CEO | — | 1 job opening · 1 internship |
| 3 | Tyra Developer of cancer resistance therapies | $356M | 28 mo ago | 38 | Daniel Bensen Co-Founder & COO | — | 1 launch |
| 4 | Surrozen Pioneering targeted regenerative antibodies to repair tissue and restore organ function 19Product top 14%Funding top 24%News top 33%Moat top 41% All 11 signals ▾Producttop 14% Fundingtop 24% Newstop 33% Moattop 41% Innovationtop 48% Patentstop 48% Growthbottom 46% Globalbottom 40% Marketbottom 29% Fin. healthbottom 20% Techbottom 15% Product: 11 distinct product lines · Company stage: Public Funding: Raised $326M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 19/100 | $326M | 14 mo ago | 80 | — | 37 patents Wnt pathway biologics and modulators for ocular and tissue regeneration therapies | — |
| 5 | JOINN Biologics Provider of biological research services | $210M | 58 mo ago | 83 83 → 47 (-43%) · sector median -2% | Shusheng Geng Co-Founder | — | 1 partnership |
| 6 | Lightship Provider of direct-to-patient clinical trial solutions | $206M | 28 mo ago | 77 | Samantha Eells Co-Founder | — | — |
| 7 | Societal CDMO Provider of clinical trial, formulation development, packaging, and quality assurance services | $141M | 102 mo ago | 275 | — | — | — |
| 8 | NantBio Provider of drug discovery and development services for molecular biology services | $105M | 132 mo ago | — | Patrick Soon-Shiong CEO | 340 patents Antibody discovery and engineering via mRNA display and AI-driven neoepitope toxicity prediction | — |
| 9 | Autekbio Biopharma CDMO specializing in the production of therapeutic proteins and antibodies from mammalian cell… | $101M | 195 mo ago | 51 | — | — | — |
| 10 | Vial | $100M | 42 mo ago | 65 65 → 155 (+138%) · sector median -2% | Simon Burns Co-Founder & CEO | — | — |
| 11 | Crown Bioscience Developer of drugs for cancer and CVMD (Cardiovascular and Metabolic Diseases) | $86M | 105 mo ago | 18 | Armin Spura CEO | — | 1 partnership · 2 expansions |
| 12 | N-Power Medicine Provider of clinical trial services | $72M | 23 mo ago | 6 | Christer Svedman Md Co-founder | — | — |
| 13 | SFJ Pharmaceuticals Specialty pharmaceutical company based on partnering model | $70M | 158 mo ago | 12 | — | — | — |
| 14 | AllStripes Provider of information to patients and communities with the medical data for rare diseases | $67M | 57 mo ago | 85 | — | — | — |
| 15 | MycoMedica Life sciences company focused on developing therapeutic drugs derived from fungi to help prevent and treat… | $60M | 48 mo ago | 14 | Paul Stamets Co-Founder | — | — |
| 16 | Amador Provider of bioanalytical, pharmacometrics, and other services | $60M | 53 mo ago | 80 | — | — | — |
| 17 | 64x Bio Developer of cell lines and production technologies for advanced therapies | $60M | 52 mo ago | 18 18 → 21 (+17%) · sector median -2% | David Thompson Co-Founder | — | 2 launchs |
| 18 | CancerVax Limited information available | $58M | 32 mo ago | 3 | David Hale CEO | 6 patents Cancer immunotherapies, angiogenesis inhibitors, and tumor antigen detection diagnostics | — |
| 19 | Certis Oncology Solutions Provider of oncology-based in-vivo drugs development services | $42M | 29 mo ago | 41 41 → 39 (-5%) · sector median -2% | James Berglund Founder & Director | 12 patents Patents concentrated in computing, sensing & instrumentation | 1 partnership |
| 20 | Optimer Pharmaceuticals Limited information available | $40M | 201 mo ago | 281 | — | 152 patents Fidaxomicin-based antibiotics for treating Clostridioides difficile and recurrent bacterial infections | — |
| 21 | Ember LifeSciences Provider of cold chain logistics services for biopharma sector 35Patents top 28%Funding top 32%Innovation top 34%News top 39% All 9 signals ▾Patentstop 28% Fundingtop 32% Innovationtop 34% Newstop 39% Moattop 45% Techbottom 46% Globalbottom 40% Talentbottom 40% Marketbottom 16% Patents: 28 patents matched (strict assignee match) · 26 filings since 2022 vs 2 in 2017-21 Funding: Raised $37.4M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $37M | 0 mo ago | — | Clay Alexander Founder & Chairman | 28 patents Temperature‑controlled reusable shipping containers for biotech/medical sample transport | 1 job opening · 3 launchs · 1 award |
| 22 | Ocelot Bio CDMO focused on manufacturing of peptides | $36M | 62 mo ago | 20 | — | — | — |
| 23 | BioIntervene Limited information available | $36M | 59 mo ago | — | Daniela Salvemini Co-Founder | 13 patents Design and synthesis of therapeutic adenosine analogs and A3 receptor agonists. | — |
| 24 | Nivagen Pharmaceuticals Developer and contract manufacturer of generic drugs, tablets, capsules, ointment and solution | $31M | 34 mo ago | 52 | Jay S. CEO & President | — | — |
| 25 | Amber Bio CDMO focused on manufacturing generic drugs | $26M | 34 mo ago | 9 | Jacob Borrajo Co-Founder & CEO | — | — |
| 26 | Anabios Human tissue and cell provider accelerating drug discovery and development | $25M | 48 mo ago | 51 51 → 38 (-25%) · sector median -2% | — | 15 patents Cardiac safety pharmacology predictive models and ex‑vivo sensory neuron subtype profiling | — |
| 27 | Ask Gene Pharma Innovating cytokine prodrugs for safer, more effective oncology and autoimmune therapies | $20M | 49 mo ago | 24 | Jiangfeng Lu CEO | — | — |
| 28 | Antigen Discovery Proteomics services and products specializing in high-throughput protein microarray technology | $17M | 22 mo ago | 21 | Xiaowu Liang Co-Founder | 15 patents Diagnostic antigens for early Lyme disease and malaria serological assays | — |
| 29 | XDemics CDMO focused on manufacturing cell & viral based therapeutics 50Funding top 38%Tech top 45%Talent bottom 49%Global bottom 25% All 4 signals ▾Fundingtop 38% Techtop 45% Talentbottom 49% Globalbottom 25% Funding: Raised $14.8M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Tech: 30 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 50/100 | $15M | 7 mo ago | — | Christopher Thanos CEO & Chairman | — | 1 partnership |
| 30 | Fauna Bio Healthcare association involved in animal genomics 24Talent top 38%Funding top 41%Global bottom 39%Moat bottom 38% All 6 signals ▾Talenttop 38% Fundingtop 41% Globalbottom 39% Moatbottom 38% Techbottom 36% Marketbottom 23% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $13.1M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $13M | 14 mo ago | 15 15 → 22 (+47%) · sector median -2% | Ashley Zehnder Co-Founder & CEO | — | — |
| 31 | Ainos Company focused on the development of novel point-of-care testing and low-dose interferon therapeutics | $13M | 25 mo ago | 43 | Chun Tsai CEO | 24 patents Electronic nose and gas‑sensor systems for rapid chemical/medical diagnostics | — |
| 32 | Free Flow Medical Provider of minimally invasive surgery solutions | $10M | 38 mo ago | 7 | — | — | — |
| 33 | Flashpoint Therapeutics Flashpoint Therapeutics is developing nanotherapeutic candidates that can deliver precise RNA, DNA, and… | $10M | 31 mo ago | — | Adam Margolin Co-Founder & CEO | — | — |
| 34 | NanoImaging Services Provider of cryo-electron microscopy, protein production, and nanoparticle characterization services | $9M | 21 mo ago | 44 44 → 40 (-9%) · sector median -2% | Clint Potter Co-Founder | 2 patents Electron microscopy and image analysis for particulate characterization | 1 launch |
| 35 | Simulations Plus Developer of modeling and simulation software and consulting services provider 62News top 24%Product top 24%Funding top 28%Fin. health top 33% All 11 signals ▾Newstop 24% Producttop 24% Fundingtop 28% Fin. healthtop 33% Growthtop 37% AItop 45% Techtop 48% Moattop 49% Innovationbottom 48% Marketbottom 47% Globalbottom 37% News: 19 BI events in 12 mo (of 179 tracked, 10 types) · +111% YoY Product: 1 product launch event in 12 mo · 6 distinct product lines rank vs industry peers · Fliar Intelligence Index 62/100 | $8M | 11 mo ago | 197 197 → 197 (+0%) · sector median -2% | — | — | 1 job opening · 1 launch · 1 partnership |
| 36 | Verantos Provider of data validation and regulatory services to biopharma sector | $7M | 16 mo ago | 52 | Dan Riskin Chief Executive Officer | 18 patents Patents concentrated in computing, sensing & instrumentation | — |
| 37 | Serotiny Provider of drug research and development services for cell & gene therapies | $7M | 38 mo ago | 12 | — | 12 patents Engineered conditional immune cell receptors for targeted immunotherapy applications. | — |
| 38 | Macro Provider of clinical trial and research services | $6M | 35 mo ago | 10 | Babak Azizzadeh Md Facs Co-Founder | 8 patents Fluid coupling and dispensing hardware, including rapid‑connect, vented, anti‑recoil couplers and tension indicators. | — |
| 39 | Cromatic Provider of a digital connectivity platform for matching clients with CROs | $5M | 31 mo ago | 10 | Ann Lin CEO | — | — |
| 40 | Synlico CRO focused on providing cancer drug discovery and development services | $5M | 15 mo ago | 8 | Jingwei Lu Founder & CEO | — | 2 awards |
| 41 | Trial Library Provider of clinical trial for drug research & development services 29Growth top 35%Funding top 43%Tech top 50%Global bottom 36% All 5 signals ▾Growthtop 35% Fundingtop 43% Techtop 50% Globalbottom 36% Marketbottom 13% Growth: Fresh capital in last 24 mo Funding: Raised $5.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $5M | 6 mo ago | 9 | — | — | 1 job opening |
| 42 | Excellos CDMO focused on providing manufacturing services for cell & gene therapy products | $5M | 25 mo ago | 32 | David Wellis CEO | — | — |
| 43 | PERSIST.AI CDMO focused on manufacturing formulations for biopharma sectors | $4M | 12 mo ago | 11 | Christopher Shelner Co-Founder & COO | — | — |
| 44 | Cellebration Life Sciences Provider of research, development, and manufacturing services for biologic drugs | $3M | 34 mo ago | 8 | Tim Kopatich Co-Founder & CEO | — | — |
| 45 | Proteas Bioanalytics CRO offering research on assays for pre-clinical and clinical biospecimens | $2M | 13 mo ago | 3 | Spiros Garbis Founder | President | CTO | 7 patents Mass spectrometry sample prep, chromatography, and data analysis for biomarker detection | — |
| 46 | Strategikon Provider of SaaS solutions for clinical trial management | $2M | 13 mo ago | — | Paulo Carvalho Co-Founder & COO | — | — |
| 47 | SUPERFLUID Company specializing in translational science and data analysis for molecular diagnostics and tissue and… | $2M | 29 mo ago | — | Gajus Worthington CEO | 2 patents Detecting splice junctions in extracellular cell‑free mRNA using bioinformatics platforms | — |
| 48 | Amaros Provider of AI based ophthalmology clinical trial services | $1M | 15 mo ago | 7 | — | — | 1 partnership |
| 49 | Percept Provider of drug repurposing engine for combination therapeutics clinical development | $570K | 14 mo ago | — | Thomas Zheng Co-Founder | 30 patents Adaptive personalized optical eyewear integrating eye‑tracking, display and vision‑enhancement technologies. | — |
| 50 | Anto Biosciences Developer of microbiology tools to improve food and drug design | $500K | 8 mo ago | — | Arvid Gollwitzer Co-Founder | — | — |
Top 12 Biopharma Outsourcing companies in California
#1
Series D · San Diego, California · founded 1995 · 1767 employees$2Braised▾
Series D · San Diego, California · founded 1995 · 1767 employees
Provider of supply chain services for biopharma sector
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 15%Product
top 26%Innovation
top 30%Growth
top 35%Market
top 43%Tech
top 43%Funding: Raised $2.0B across 10 rounds · 10 rounds over 20 yrs (0.5/yr) · Last round Venture Debt (Oct 2025)
Product: 3 distinct product lines · Company stage: Series D
Innovation: 3 product lines
Audience (LinkedIn): 49k LinkedIn followers — 20.3% of this cohort's audience
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- Oct 2025Venture Debt$825M
- Oct 2024Grant (prize money)$17.5M
- Mar 2023Conventional Debt$410M
- Jan 2023Series D—
Founders & team
Investors
Mubadala, Kennet Partners, BPEA, Defense.gov, DFC, Arch Venture Partners
Tech stack
Amazon Web ServicesApple Icloud MailCdnjsCloudflareCloudflare Bot ManagementCore-Js
#2
Series B · San Francisco, California · founded 2023$554Mraised▾
Series B · San Francisco, California · founded 2023
Biotech company developing personalized medicines for cardiovascular diseases. It is a biotechnology company focused on developing precision medicines for cardiovascular disease. The company aims to modernize cardiovascular drug development with a late-stage portfolio of personalized medicines.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 14%Growth
top 28%Tech
top 48%Talent
bottom 49%Market
bottom 35%Global
bottom 33%Funding: Raised $554M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Series B (Oct 2025)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Tech: 30 technologies across 3/8 capability areas · Cloud: Cloudflare · Security: Cloudflare Bot Management, Http/3
Audience (LinkedIn): 9k LinkedIn followers — 3.9% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: clinical trial leads, biostatistics experts
Funding rounds
- Oct 2025Series B$254M
- Jan 2025Series A$300M
Founders & team
Investors
Perceptive Advisors, Arch Venture Partners, Sequoia Heritage, Fidelity Investments, T. Rowe Price
Tech stack
AccessibeApple Icloud MailCloudflareCloudflare Bot ManagementDiviDocusign
#3
Series A · Westlake Village, California · founded 2022$37.4Mraised▾
Series A · Westlake Village, California · founded 2022
Provider of cold chain logistics services for biopharma sector
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Patents
top 28%Funding
top 32%Innovation
top 34%News
top 39%Moat
top 45%Tech
bottom 46%Patents: 28 patents matched (strict assignee match) · 26 filings since 2022 vs 2 in 2017-21 · Latest publication 2026
Funding: Raised $37.4M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Series A (May 2026)
Innovation: 28 patents (top 43% of patent-holders) · 26 filings since 2022 vs 2 in 2017-21
Audience (LinkedIn): 1k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public)
Activity (LinkedIn): 3 product launches · 1 awards announced in 12 mo
Funding rounds
- Dec 2025Series A$16.5M
- Jun 2025Series A$20.9M
- Feb 2023Seed—
Founders & team
Investors
Carrier, Cardinal Health, Amgen, TDF Ventures, Gozde Tech Ventures
#4
Public · San Francisco, California · founded 2016 · 80 employees$326Mraised▾
Public · San Francisco, California · founded 2016 · 80 employees
Pioneering targeted regenerative antibodies to repair tissue and restore organ function. This company is developing a new class of therapeutics focused on tissue regeneration. Through selective activation of the Wnt pathway with targeted antibodies, they aim to treat serious diseases characterized by tissue injury. They design tissue-specific antibodies that engage the body’s own biological repair mechanisms, developing a pipeline of first-in-class drug candidates. Their platform promises to overcome limitations of regenerative medicines. Combining Wnt pathway biology understanding with advanced antibody engineering, they design tissue-specific antibodies with the potential to regenerate tissue across various organs and tissues. They are currently focused on Ophthalmology, addressing severe eye diseases. Their uniquely-engineered antibodies selectively modulate the Wnt pathway to repair tissue damage and improve organ function. Their vision is to engage the body’s own biological tissue repair mechanisms with their targeted regenerative antibodies.
Fliar Intelligence Index™ 19how this company ranks against its industry peers
Product
top 14%Funding
top 24%News
top 33%Moat
top 41%Innovation
top 48%Patents
top 48%Product: 11 distinct product lines · Company stage: Public
Funding: Raised $326M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) · Last round Post IPO (Mar 2025)
News: 22 BI events in 12 mo (of 33 tracked, 5 types) · +1000% YoY · Top themes: Acquisition, Leadership
Funding rounds
- Mar 2025Post IPO$175M
- Apr 2024Post IPO$193M
- Jun 2020Series C$50M
- Mar 2019Series B$50M
Investors
The Column Group, Horizons Ventures, Hartford HealthCare, Timefolio Capital, Venrock, Access Biotechnology
Tech stack
WebflowJqueryGoogle Hosted LibrariesGoogle Font Api
#5
Series B · Monrovia, California · founded 2017$14.8Mraised▾
Series B · Monrovia, California · founded 2017
CDMO focused on manufacturing cell & viral based therapeutics
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 38%Tech
top 45%Talent
bottom 49%Global
bottom 25%Funding: Raised $14.8M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) · Last round Series B (Oct 2025)
Tech: 30 technologies across 4/8 capability areas · Cloud: Cloudflare · Security: Cloudflare Bot Management, Hsts
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Omios Biologics) announced in 12 mo
Funding rounds
- Oct 2025Series B$7.4M
- Nov 2024Series A$5.5M
- May 2024Seed$1.9M
Founders & team
Tech stack
American ExpressApple PayCart FunctionalityCdnjsCloudflareCloudflare Bot Management
#6
Series A · San Francisco, California · founded 2018 · 9 employees$5Mraised▾
Series A · San Francisco, California · founded 2018 · 9 employees
Provider of clinical trial for drug research & development services
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Growth
top 35%Funding
top 43%Tech
top 50%Global
bottom 36%Market
bottom 13%Growth: Fresh capital in last 24 mo
Funding: Raised $5.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series A (Dec 2025)
Tech: 20 technologies across 4/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 · Security: Hsts
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Patient Navigator, Staff Engineer, Backend & Data
Funding rounds
- Dec 2025Series A$10M
- Aug 2022Seed$5M
Investors
Unseen Capital, SemperVirens, NEXT VENTURES, Sanofi Ventures, Lux Capital, Civilization Ventures
Tech stack
Amazon CloudfrontAmazon S3Amazon SesAmazon Web ServicesCookieyesEmotion
#7
Public · Lancaster, California · founded 1996 · 197 employees$8Mraised▾
Public · Lancaster, California · founded 1996 · 197 employees
Developer of modeling and simulation software and consulting services provider. The company offers software for pharmacokinetic modeling, machine learning, and quantitative systems pharmacology. Consulting services include early drug discovery, clinical pharmacology, and medical communications.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
News
top 24%Product
top 24%Funding
top 28%Fin. health
top 33%Growth
top 37%AI
top 45%News: 19 BI events in 12 mo (of 179 tracked, 10 types) · +111% YoY · Top themes: Earnings, New product
Product: 1 product launch event in 12 mo · 6 distinct product lines · Company stage: Public
Funding: Raised $8.0M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) · Last round Grant (prize money) (Jun 2025)
Audience (LinkedIn): 13k LinkedIn followers — 5.3% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Associate Product Specialist
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. NVIDIA) announced in 12 mo
Funding rounds
- Jun 2025Grant (prize money)$499K
- Mar 2025Grant (prize money)$500K
- Feb 2025Grant (prize money)$500K
- Nov 2024Grant (prize money)—
Investors
NIH, FDA, HHS
Tech stack
Apple Icloud MailAzureCookieyesDropboxFastlyGoogle Analytics
#8
Seed · Berkeley, California · founded 2018 · 15 employees$13.1Mraised▾
Seed · Berkeley, California · founded 2018 · 15 employees
Healthcare association involved in animal genomics
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Talent
top 38%Funding
top 41%Global
bottom 39%Moat
bottom 38%Tech
bottom 36%Market
bottom 23%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $13.1M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) · Last round Seed (Apr 2025)
Global: Investors from 6 countries beyond United States
Audience (LinkedIn): 6k LinkedIn followers — 2.4% of this cohort's audience
Funding rounds
- Apr 2025Seed—
- Nov 2024Grant (prize money)$244.1K
- Sep 2021Seed$9M
- 2021Grant (prize money)$373.4K
Founders & team
Investors
True Ventures, The Longevity Fund, Pacific 8 Ventures, Boom Capital Ventures, Beagle Ventures, Lifeforce Capital
#9
Public · Carlsbad, California · founded 2018 · 38 employees$356Mraised▾
Public · Carlsbad, California · founded 2018 · 38 employees
Developer of cancer resistance therapies
LinkedIn Pulse recent public activity · Jul 2026
Audience: 11k LinkedIn followers — 4.8% of this cohort's audience · 33 engagements/post (1.7× cohort median)
Activity: 1 product launches announced in 12 mo
Funding rounds
- Feb 2024Post IPO$200M
- Mar 2021Series B$106M
- Jan 2020Series A$50M
Founders & team
Investors
Alta Partners, RA Capital Management, Boxer Capital, Canaan, Nextech Invest, BVF Partners
Tech stack
CloudflareCloudflare Bot ManagementContact Form 7CookieyesCore-JsDivi
#10
Series B · Redwood City, California · founded 2021 · 6 employees$72Mraised▾
Series B · Redwood City, California · founded 2021 · 6 employees
Provider of clinical trial services
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Funding rounds
- Jul 2024Series B—
Founders & team
Investors
Merck Global Health Innovation Fund
Tech stack
Amazon CloudfrontAmazon S3Amazon Web ServicesAtlassian StatuspageDocusignOpen Graph
#11
Series D · El Segundo, California · founded 1995 · 77 employees$205.5Mraised▾
Series D · El Segundo, California · founded 1995 · 77 employees
Provider of direct-to-patient clinical trial solutions
LinkedIn Pulse recent public activity · Jul 2026
Audience: 9k LinkedIn followers — 3.8% of this cohort's audience
Funding rounds
- Feb 2024Series D$135.5M
- Sep 2021Series C$40M
- Apr 2021Series B$10M
- Feb 2020Series B$20M
Founders & team
Investors
McKesson Ventures, Define Ventures, Khosla Ventures, McKesson, ATEL Capital Group, Hikma Ventures
Tech stack
Apple Icloud MailCore-JsDocusignElementorGodaddyGoogle Font Api
#12
Series A · Woodland, California · founded 2022 · 11 employees$4.3Mraised▾
Series A · Woodland, California · founded 2022 · 11 employees
CDMO focused on manufacturing formulations for biopharma sectors
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Hiring: 1 hiring post in 12 mo (public) · hiring: Inside Sales Representative
Activity: 1 partnerships (incl. CyanoCapture) announced in 12 mo
Funding rounds
- May 2025Series A$12M
- 2023Seed$500K
- May 2023Seed$4.2M
Founders & team
Investors
2048 Ventures, Fellows Fund, Y Combinator, Pioneer Fund, Innospark, Spero Ventures
Funding & investor landscape
$5.3Btotal disclosed funding
102companies funded
267disclosed rounds
0rounds last 90 days
Most active investors
Y Combinator4 rounds
Notable founders
Rahul Singhvi
ex-Co-Founder · Resilience
Tassos Gianakakos
Co-Founder & CEO · Kardigan
Clay Alexander
Founder & Chairman · Ember LifeSciences
Christopher Thanos
CEO & Chairman · XDemics
Ashley Zehnder
Co-Founder & CEO · Fauna Bio
Katie Grabek
Co-Founder & CSO · Fauna Bio
Daniel Bensen
Co-Founder & COO · Tyra
Todd Harris
Founder & CEO · Tyra
Christer Svedman Md
Co-founder · N-Power Medicine
Mark Lee
CEO & Co-Founder · N-Power Medicine
Samantha Eells
Co-Founder · Lightship
Brian Lovett
Co-Founder · Lightship
Prism market signals · United States · country-scoped Prism corpus, 1,368,075 docs
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN CALIFORNIA · Health & Bio
How research on Biotechnology in California is moving
A read on the academic research around Biotechnology in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 465 papers.
UC Davis, Berkeley, and Irvine lead California's optimistically-toned biotechnology research, predominantly exploring CRISPR, genetic engineering, and RNA mechanisms across 465 papers with a cautiously hopeful mean stance of 0.52.
465 papers · stance +0.52 · 47% breakthrough · 15% concern
top institutions
- University of California, Davis74
- University of California, Berkeley57
- University of California, Irvine51
- University of California, San Francisco49
- University of California, Los Angeles43
leading researchers
Suhas Sureshchandra · A. R. Kurhe · R. R. Raut · S. S. Mirza · G. D. Suryawanshi · Blake A. Simmons
prism intelligence · tone & topics
90% positive · 4% critical tone
Medical ResearchHealthPharmaceuticalsBiologyAgricultureGenetics
▲
Breakthroughs187 · 40%
▼ 43%→39% share
▼0.9× share momentum0 median citations64% since 2021mostly empirical
Gene-editing research is surging — Gene, Gene knockdown, Genome, and Genomics topics collectively jumped from 6 to 30+ papers.
rising sub-themes (early→recent)
- Gene6→18
- Transcription (linguistics)2→9
- Gene expression3→9
- Mutant2→6
- DNA methylation4→8
Newly emergingGene knockdown 0→6 · Genome 0→6 · Genomics 0→6
Landmark RNA-programmed genome editing in human cells · 2,139 cites
◆
Advancements154 · 33%
▼ 37%→32% share
▼0.9× share momentum0 median citations64% since 2021mostly empirical
Vermicompost-related biotech newly emerged — Compost, Eisenia fetida, and Vermicompost each debuted at 6–7 papers.
rising sub-themes (early→recent)
- Gene1→6
- DNA damage1→5
- Transcriptome1→4
- Population1→4
- Bacteria1→3
Newly emergingCompost 0→7 · Eisenia fetida 0→6 · Vermicompost 0→6
Landmark Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS–) vs. Alternatively Activated · 2,029 cites
▼
Concerns60 · 13%
▼ 13%→12% share
▼0.9× share momentum0 median citations63% since 2021mostly empirical
Cancer and public health risks newly flagged — Cancer, Cancer cell, and Public health each entered at 3 papers this period.
rising sub-themes (early→recent)
- Population2→4
Newly emergingCancer 0→3 · Cancer cell 0→3 · Public health 0→3
Landmark Beneficial Biofuels—The Food, Energy, and Environment Trilemma · 1,582 cites
Common questions
How many Biopharma Outsourcing companies are there in California, United States?
Radar tracks 375 indexable Biopharma Outsourcing companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Biopharma Outsourcing companies in California, United States?
The Biopharma Outsourcing companies in California, United States on this list have raised a combined $5.3B in disclosed equity funding across 102 funded companies.
Which is the highest-funded Biopharma Outsourcing company in California, United States?
Resilience is the highest-funded Biopharma Outsourcing company in California, United States, with $2B in disclosed equity funding.
How many Biopharma Outsourcing companies in California, United States are funded?
102 of the 375 Biopharma Outsourcing companies in California, United States on this list have disclosed at least one equity funding round.
How many Biopharma Outsourcing unicorns are there in California, United States?
None of the Biopharma Outsourcing companies in California, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in California, United States Biopharma Outsourcing companies?
The most active investors in California, United States Biopharma Outsourcing companies on this list include HHS, National Science Foundation, NIH, Ampersand Capital, Bay City Capital.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.